High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety.

MLA

Wiedermann CJ, et al. “High-Dose Antithrombin III in the Treatment of Severe Sepsis in Patients with a High Risk of Death: Efficacy and Safety.” Critical Care Medicine, vol. 34, no. 2, Feb. 2006, pp. 285–92. EBSCOhost, https://doi.org/10.1097/01.ccm.0000194731.08896.99.

APA

Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Keinecke H, Warren BL, Opal SM, KyberSept Investigators, Wiedermann, C. J., Hoffmann, J. N., Juers, M., Ostermann, H., Kienast, J., Briegel, J., Strauss, R., Keinecke, H.-O., & Warren, B. L. (2006). High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical Care Medicine, 34(2), 285–292. https://doi.org/10.1097/01.ccm.0000194731.08896.99

Chicago

Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, et al. 2006. “High-Dose Antithrombin III in the Treatment of Severe Sepsis in Patients with a High Risk of Death: Efficacy and Safety.” Critical Care Medicine 34 (2): 285–92. doi:10.1097/01.ccm.0000194731.08896.99.